aTYR PHARMA INC

ATYR Nasdaq CIK: 0001339970

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
Mailing Address 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
Phone 8587318389
Fiscal Year End 1231
EIN 203435077

Financial Overview

FY2025

$-0.80
EPS

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement March 26, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
10-K Annual financial report March 5, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report January 9, 2026 View on SEC
4 Insider stock transaction report January 9, 2026 View on SEC
4 Insider stock transaction report January 9, 2026 View on SEC

Annual Reports

10-K March 5, 2026
  • Clinical-stage biopharmaceutical company leveraging a proprietary technology platform to advance a drug pipeline.
  • Business model includes collaboration and licensing agreements as a primary source of revenue.
View Analysis

Material Events

8-K Financial Distress December 5, 2025
High Impact
  • aTYR PHARMA INC received a deficiency notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share.
  • The company's stock price closed below $1.00 for 30 consecutive business days, violating Nasdaq's listing requirements.
View Analysis

Insider Trading

SELL 3 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.